Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease
Dimitrios D Raptis,Christos S Mantzoros,Stergios A Polyzos
DOI: https://doi.org/10.2147/TCRM.S352008
2023-01-23
Therapeutics and Clinical Risk Management
Abstract:Dimitrios D Raptis, 1, 2 Christos S Mantzoros, 3, 4 Stergios A Polyzos 1 1 First Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece; 2 Second Department of Internal Medicine, 424 General Military Hospital, Thessaloniki, Greece; 3 Department of Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; 4 Department of Internal Medicine, Boston VA Healthcare System, Harvard Medical School, Boston, MA, 02115, USA Correspondence: Stergios A Polyzos, First Laboratory of Pharmacology, School of Medicine, Campus of Aristotle University of Thessaloniki, Thessaloniki, 54124, Greece, Tel +30 2310 999316, Email Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent disease without any approved treatment to-date despite intensive research efforts by researchers and pharmaceutical industry. Fibroblast growth factor (FGF)-21 has been gaining increasing attention as a possible contributing factor and thus therapeutic target for obesity-related metabolic disorders, including NAFLD, mainly due to its effects on lipid and carbohydrate metabolism. Most animal and human observational studies have shown higher FGF-21 concentrations in NAFLD than non-NAFLD, implying that FGF-21 may be increased to counteract hepatic steatosis and inflammation. However, although Mendelian Randomization studies have revealed that variations of FGF-21 levels within the physiological range may have effects in hyperlipidemia and possibly nonalcoholic steatohepatitis, they also indicate that FGF-21, in physiological concentrations, may fail to reverse NAFLD and may not be able to control obesity and other diseases, indicating a state of FGF-21 resistance or insensitivity that could not respond to administration of FGF-21 in supraphysiological concentrations. Interventional studies with FGF-21 analogs (eg, pegbelfermin, efruxifermin, BOS-580) in humans have provided some favorable results in Phase 1 and Phase 2 studies. However, the definite effect of FGF-21 on NAFLD may be clarified after the completion of the ongoing clinical trials with paired liver biopsies and histological endpoints. The aim of this review is to critically summarize experimental and clinical data of FGF-21 in NAFLD, in an attempt to highlight existing knowledge and areas of uncertainty, and subsequently, to focus on the potential therapeutic effects of FGF-21 and its analogs in NAFLD. Keywords: hepatic fibrosis, hepatic inflammation, hepatic steatosis, hepatokine, nonalcoholic steatohepatitis, treatment Nonalcoholic fatty liver disease (NAFLD) has been closely associated with the metabolic syndrome (MetS); this has led to the recommendation of change in the disease nomenclature including a change to simply Fatty Liver Disease (FLD) or to metabolic (dysfunction)-associated fatty liver disease (MAFLD). 1,2 In the setting of increasing prevalence of obesity and metabolic dysregulation in western societies, there has been a global increase in the prevalence of NAFLD, in parallel with type 2 diabetes mellitus (T2DM) and obesity epidemics. Notably, NAFLD may often remain underdiagnosed, provoking undesirable individual and public consequences. 3 NAFLD demonstrates a wide histological spectrum, gradually ranging from simple nonalcoholic fatty liver (NAFL), to nonalcoholic steatohepatitis (NASH), hepatic fibrosis, liver cirrhosis and hepatocellular carcinoma (HCC) in a minority of patients, which appears in the absence of significant alcohol consumption, viral infection or any other specific hepatic disease. 4 It is expected that NAFLD may possibly become the leading cause of liver transplantation in the near future. 5 Despite its high prevalence and the extensive research in the field, the treatment of NAFLD remains an unmet medical need, since there is to-date no medication specifically licensed for NAFLD. 6 NAFL starts as a state of imbalance between factors favoring fat export vs factors favoring fat accumulation in the liver. 4 Insulin resistance (IR) interplays with systemic and hepatic inflammation, through various adipokines, cytokines, hepatokines and other mediators, to increase the load of free fatty acids that divert from adipose tissue to the liver, but also hepatic de novo lipogenesis, thus favoring fat accumulation in the liver. 7 Adipokines, cytokines, hepatokines and other mediators seem to contribute to the pathogenesis of the disease, thus being appealing therapeutic targets. 8 Fibroblast growth factors (FGF) comprise a family of peptidic molecules, which are widely expressed; by activating FGF receptors (FGFR), FGFs contribute to the repair and regeneration of tissues, but also to metabolic h -Abstract Truncated-
health care sciences & services